Chapter 5 · Behind the Numbers
The quarter, in
Lilly's own
words.
Management's framing of what just happened — and what it's watching.
↓ scroll to read
✦ The bottom line
Anyone can read the revenue line. The story — why it moved, what's driving it, what's next — is the part Lilly narrates itself. Seven threads from the quarter.
↓ the brief below
✦ Seven threads from the Q1 2026 earnings release
1
A blockbuster quarter — and raised guidance.
Revenue grew 56% to $19.8 billion and operating income 141%; Lilly raised full-year revenue guidance by $2 billion to $82-85 billion.
2
One molecule, two names.
Mounjaro (diabetes) grew 125% to $8.7B and Zepbound (obesity) grew 80% to $4.2B — together about two-thirds of all revenue.
3
Volume, not price.
Growth came from a 65% jump in volume, partly offset by a 13% decline in realized prices — Lilly is selling far more, at lower prices.
4
International is accelerating.
Revenue outside the U.S. grew 81%, helped by adding Mounjaro to China's national reimbursement list — opening a vast new market.
5
The pipeline is delivering.
The FDA approved Foundayo (orforglipron), an oral GLP-1 pill, and the triple-agonist retatrutide posted positive Phase 3 results in type 2 diabetes.
6
Margins stayed elite.
Gross margin held near 82% even as prices fell, while R&D rose 28% to $3.5 billion — Lilly out-spending to stay ahead.
7
Reinvesting the windfall.
Lilly agreed to acquire four biotech companies in the quarter and is spending heavily to expand manufacturing capacity.
Source · 8-K · Item 2.02 — earnings release, CEO commentary & financials · Q1 2026 · Filed Apr 30, 2026